Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Liabilities and Shareholders Equity (2016 - 2025)

Macrogenics (MGNX) has disclosed Liabilities and Shareholders Equity for 14 consecutive years, with $256.8 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 1.84% to $256.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $997.6 million through Dec 2025, up 2.26% year-over-year, with the annual reading at $256.8 million for FY2025, 1.84% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $256.8 million at Macrogenics, down from $270.8 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $435.4 million in Q1 2021, with the low at $195.3 million in Q3 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $290.7 million, with a median of $271.1 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity tumbled 50.19% in 2022, then soared 74.03% in 2023.
  • Over 5 years, Liabilities and Shareholders Equity stood at $335.2 million in 2021, then dropped by 16.34% to $280.5 million in 2022, then grew by 6.4% to $298.4 million in 2023, then decreased by 12.32% to $261.7 million in 2024, then dropped by 1.84% to $256.8 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $256.8 million, $270.8 million, and $245.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.